Skip to Main Content

Author Details

Alana L Welm
Huntsman Cancer Institute, University of Utah
1999
97
42
PMIDPaper TitleJournal TitlePublished Year
37188526Breast Cancer Immunity: It is TIME for the Next Chapter.Cold Spring Harb Perspect Med2024
37188526Breast Cancer Immunity: It is TIME for the Next Chapter.Cold Spring Harb Perspect Med2024
36876914Transferred mitochondria accumulate reactive oxygen species, promoting proliferation.Elife2023
37402170Breast cancer PDxO cultures for drug discovery and functional precision oncology.STAR Protoc2023
37275275Estrogen receptor alpha mutations regulate gene expression and cell growth in breast cancer through microRNAs.NAR Cancer2023
36876914Transferred mitochondria accumulate reactive oxygen species, promoting proliferation.Elife2023
37450351Endocrine Therapy Synergizes with SMAC Mimetics to Potentiate Antigen Presentation and Tumor Regression in Hormone Receptor-Positive Breast Cancer.Cancer Res2023
37450351Endocrine Therapy Synergizes with SMAC Mimetics to Potentiate Antigen Presentation and Tumor Regression in Hormone Receptor-Positive Breast Cancer.Cancer Res2023
37275275Estrogen receptor alpha mutations regulate gene expression and cell growth in breast cancer through microRNAs.NAR Cancer2023
37402170Breast cancer PDxO cultures for drug discovery and functional precision oncology.STAR Protoc2023
33274845Ligand-based Discovery of Novel Small Molecule Inhibitors of RON Receptor Tyrosine Kinase.Mol Inform2022
35773258Improving the odds together: a framework for breast cancer research scientists to include patient advocates in their research.NPJ Breast Cancer2022
36088362Immunologically "cold" triple negative breast cancers engraft at a higher rate in patient derived xenografts.NPJ Breast Cancer2022
36007109Dll1-Mediated Notch Signaling Drives Tumor Cell Cross-talk with Cancer-Associated Fibroblasts to Promote Radioresistance in Breast Cancer.Cancer Res2022
35808806Single-cell RNA sequencing reveals localized tumour ablation and intratumoural immunostimulant delivery potentiate T cell mediated tumour killing.Clin Transl Med2022
35490197Low-affinity CAR T cells exhibit reduced trogocytosis, preventing rapid antigen loss, and increasing CAR T cell expansion.Leukemia2022
35798701Author Correction: Dll1+ quiescent tumor stem cells drive chemoresistance in breast cancer through NF-κB survival pathway.Nat Commun2022
36619972Identifying biomarkers of differential chemotherapy response in TNBC patient-derived xenografts with a CTD/WGCNA approach.iScience2022
33274845Ligand-based Discovery of Novel Small Molecule Inhibitors of RON Receptor Tyrosine Kinase.Mol Inform2022
35235778CDK/cyclin dependencies define extreme cancer cell-cycle heterogeneity and collateral vulnerabilities.Cell Rep2022
34951956Functional precision oncology: Testing tumors with drugs to identify vulnerabilities and novel combinations.Cancer Cell2022
35121993Astrocytic laminin-211 drives disseminated breast tumor cell dormancy in brain.Nat Cancer2022
34996889Author Correction: Comprehensive characterization of 536 patient-derived xenograft models prioritizes candidates for targeted treatment.Nat Commun2022
35221336A human breast cancer-derived xenograft and organoid platform for drug discovery and precision oncology.Nat Cancer2022
35808806Single-cell RNA sequencing reveals localized tumour ablation and intratumoural immunostimulant delivery potentiate T cell mediated tumour killing.Clin Transl Med2022
35773258Improving the odds together: a framework for breast cancer research scientists to include patient advocates in their research.NPJ Breast Cancer2022
35798701Author Correction: Dll1+ quiescent tumor stem cells drive chemoresistance in breast cancer through NF-κB survival pathway.Nat Commun2022
35490197Low-affinity CAR T cells exhibit reduced trogocytosis, preventing rapid antigen loss, and increasing CAR T cell expansion.Leukemia2022
36619972Identifying biomarkers of differential chemotherapy response in TNBC patient-derived xenografts with a CTD/WGCNA approach.iScience2022
36088362Immunologically "cold" triple negative breast cancers engraft at a higher rate in patient derived xenografts.NPJ Breast Cancer2022
36007109Dll1-Mediated Notch Signaling Drives Tumor Cell Cross-talk with Cancer-Associated Fibroblasts to Promote Radioresistance in Breast Cancer.Cancer Res2022
34951956Functional precision oncology: Testing tumors with drugs to identify vulnerabilities and novel combinations.Cancer Cell2022
35221336A human breast cancer-derived xenograft and organoid platform for drug discovery and precision oncology.Nat Cancer2022
35121993Astrocytic laminin-211 drives disseminated breast tumor cell dormancy in brain.Nat Cancer2022
34996889Author Correction: Comprehensive characterization of 536 patient-derived xenograft models prioritizes candidates for targeted treatment.Nat Commun2022
35235778CDK/cyclin dependencies define extreme cancer cell-cycle heterogeneity and collateral vulnerabilities.Cell Rep2022
33415312Toward improved models of human cancer.APL Bioeng2021
34077726Inhibiting an RBM39/MLL1 epigenomic regulatory complex with dominant-negative peptides disrupts cancer cell transcription and proliferation.Cell Rep2021
33462238Dll1<sup>+</sup> quiescent tumor stem cells drive chemoresistance in breast cancer through NF-κB survival pathway.Nat Commun2021
34104847Erratum: "Toward improved models of human cancer" [APL Bioeng. <b>5</b>, 010901 (2021)].APL Bioeng2021
33561396Heterogeneity in Metastatic Potential of Cancer Cells Is Revealed En Masse.Cancer Cell2021
34344433Evaluation of FGFR targeting in breast cancer through interrogation of patient-derived models.Breast Cancer Res2021
34330779Blocking Short-Form Ron Eliminates Breast Cancer Metastases through Accumulation of Stem-Like CD4+ T Cells That Subvert Immunosuppression.Cancer Discov2021
33257837RON signalling promotes therapeutic resistance in ESR1 mutant breast cancer.Br J Cancer2021
33239679The lingering mysteries of metastatic recurrence in breast cancer.Br J Cancer2021
33417832An Embryonic Diapause-like Adaptation with Suppressed Myc Activity Enables Tumor Treatment Persistence.Cancer Cell2021
33415312Toward improved models of human cancer.APL Bioeng2021
34717714An immune-humanized patient-derived xenograft model of estrogen-independent, hormone receptor positive metastatic breast cancer.Breast Cancer Res2021
34711608Transcriptional Reprogramming Differentiates Active from Inactive ESR1 Fusions in Endocrine Therapy-Refractory Metastatic Breast Cancer.Cancer Res2021
34429404Comprehensive characterization of 536 patient-derived xenograft models prioritizes candidatesfor targeted treatment.Nat Commun2021
  • 1 - 50 of 194

Recommended Authors

Cristina Ivan
The University of Texas MD Anderson Cancer Center
Career Start Year 2010
Number of shared co-authors 4
Aleksandra M Michalowski
Center for Cancer Research, National Cancer Institute
Career Start Year 2010
Number of shared co-authors 0
Chad V Pecot
University of North Carolina at Chapel Hill
Career Start Year 2009
Number of shared co-authors 4
Yang Chen
The University of Texas MD Anderson Cancer Center
Career Start Year 2008
Number of shared co-authors 0
Bora Lim
The University of Texas MD Anderson Cancer Center
Career Start Year 2007
Number of shared co-authors 2
Jonathan Chou
University of California san francisco
Career Start Year 2005
Number of shared co-authors 3
Arnulfo Mendoza
National Cancer Institute, National Institutes of Health
Career Start Year 2004
Number of shared co-authors 0
Jalna Meens
Princess Margaret Cancer Centre, University Health Network
Career Start Year 2004
Number of shared co-authors 0
Xiaohu Zhang
National Center for Advancing Translational Sciences
Career Start Year 2003
Number of shared co-authors 1
Darran P O'Connor
UCD Conway Institute, University College Dublin
Career Start Year 2001
Number of shared co-authors 6
Jun Yao
The University of Texas MD Anderson Cancer Center
Career Start Year 1997
Number of shared co-authors 4
Hai Hu
Sun Yat-sen Memorial Hospital, Sun Yat-sen University
Career Start Year 1996
Number of shared co-authors 3
William M Gallagher
All-Island Cancer Research Institute, UCD Conway Institute, University College Dublin
Career Start Year 1996
Number of shared co-authors 9
Theresa M LaVallee
Parker Institute for Cancer Immunotherapy
Career Start Year 1996
Number of shared co-authors 0
Naoto T Ueno
Cancer Research Center of Hawaii: University of Hawai'i Cancer Center.
Career Start Year 1995
Number of shared co-authors 11
Alexander D Borowsky
University of California Davis Health
Career Start Year 1995
Number of shared co-authors 6
Zhaomei Mu
Thomas Jefferson University Hospital
Career Start Year 1994
Number of shared co-authors 1
Andrei Goga
University of California San Francisco
Career Start Year 1993
Number of shared co-authors 6
Rozita Bagheri-Yarmand
The University of Texas MD Anderson Cancer Center
Career Start Year 1992
Number of shared co-authors 1
Senthil K Muthuswamy
Center for Cancer Research, National Cancer Institute, National Institutes of Health
Career Start Year 1992
Number of shared co-authors 5
Kornelia Polyak
Dana-Farber Cancer Institute, Brigham and Women's Hospital, Harvard Medical School
Career Start Year 1991
Number of shared co-authors 14
Ben Ho Park
Vanderbilt University Medical Center
Career Start Year 1990
Number of shared co-authors 7
Wei Zhang
The University of Texas MD Anderson Cancer Center
Career Start Year 1988
Number of shared co-authors 5
Eldad Zacksenhaus
University of Toronto
Career Start Year 1988
Number of shared co-authors 3
Rakesh Kumar
Rutgers New Jersey Medical School
Career Start Year 1987
Number of shared co-authors 4
Louis Gaboury
Institute for Research in Immunology and Cancer (IRIC), University of Montreal
Career Start Year 1986
Number of shared co-authors 1
John A Copland
Mayo Clinic Jacksonville
Career Start Year 1982
Number of shared co-authors 1
Patricia S Steeg
Center for Cancer Research, National Cancer Institute
Career Start Year 1980
Number of shared co-authors 5
Christopher C Benz
Buck Institute for Research on Aging
Career Start Year 1977
Number of shared co-authors 8
Dennis J Slamon
David Geffen School of Medicine at university of california los angeles
Career Start Year 1973
Number of shared co-authors 8

Collaborators

Bryan E Welm
Co-authored papers 15
Michael T Lewis
Baylor College of Medicine
Co-authored papers 8
Shunqiang Li
Co-authored papers 6
Matthew J Ellis
Co-authored papers 6
Lacey E Dobrolecki
Co-authored papers 5
Matthew H Bailey
Department of Biology at Brigham Young University
Co-authored papers 4
Funda Meric-Bernstam
University of Texas MD Anderson Cancer Center
Co-authored papers 4
Yvonne A Evrard
Frederick National Laboratory for Cancer Research, Inc.
Co-authored papers 3
Heidi Dowst
Dan L Duncan Comprehensive Cancer Center
Co-authored papers 3
James H Doroshow
National Cancer Institute, National Institutes of Health
Co-authored papers 3
William H Hildebrand
University of Oklahoma Health Sciences Center
Co-authored papers 3
Christopher J Lengner
Co-authored papers 3
Elisabetta Marangoni
Co-authored papers 3
Jason Gertz
Huntsman Cancer Institute, University of Utah
Co-authored papers 2
Li Ding
McDonnell Genome Institute, Washington University School of Medicine
Co-authored papers 2
Carol J Bult
The Jackson Laboratory Cancer Center
Co-authored papers 2
Sherri R Davies
Co-authored papers 2
Tina Primeau
Co-authored papers 2
John F DiPersio
Washington University School of Medicine
Co-authored papers 2
Oscar M Rueda
University of Cambridge
Co-authored papers 2
Stephen L Lessnick
The Ohio State University College of Medicine
Co-authored papers 2
Varduhi Petrosyan
Co-authored papers 2
Nadezhda V Terekhanova
Co-authored papers 2
Feng Chen
Washington University in St Louis
Co-authored papers 2
William Matsui
Livestrong Cancer Institutes, Dell Medical School, University of Texas at Austin
Co-authored papers 2
Gordon B Mills
Knight Cancer Institute, Oregon Health and Sciences University
Co-authored papers 2
Carlos Caldas
Cancer Research UK Cambridge Institute, University of Cambridge
Co-authored papers 2
Jonathan T Lei
Co-authored papers 2
Yize Li
Co-authored papers 2
Joan S Brugge
Co-authored papers 2
Release 1.2